skip to content

Investors

Roche Full Year Results 2025

Thursday, 29 January 2026 at 13:30 CET

More details

A blue-gloved hand delicately holds a small pink container with a QR code. Nearby are green, blue, and yellow containers on a white surface, indicating a scientific setting.

Roche’s Virtual Neurology/ACTRIMS Investor Event

Monday, 9 February at 16:30 CET

More details

A gloved hand in a lab coat holds a small, clear vial against a blurred background of lab equipment, conveying a scientific and clinical setting.

24 million

patients were treated with Roche medicines in 2024

30 billion

Roche Diagnostics test were delivered to customers worldwide in 2024

+1%

Core investments in research and development in 2024: CHF 13.2 billion

Our two divisions are focusing jointly on three disease areas that will account for almost 50% of the global disease burden by 2035: cancer, cardiovascular-metabolic diseases and neurological diseases.

Portrait of Thomas Schinecker

Dr Thomas Schinecker

CEO Roche Group

Upcoming Investor events

View all events

Octavian Seminar 2026Investors

January 15, 2026 at 10:00 CET | Davos, CH

Roche Full Year Results 2025 (virtual event)Investors

January 29, 2026 at 13:30 CET | Basel, Switzerland

Roche’s Virtual Neurology/ACTRIMS Investor EventInvestors

February 09, 2026 at 16:30 CET

TD Cowen 4th Annual Healthcare ConferenceInvestors

March 03, 2026 at 08:00 EST | Boston, US

UBS European Healthcare ConferenceInvestors

March 03, 2026 at 08:00 GMT | London, UK

Barclays Global Healthcare ConferenceInvestors

March 10, 2026 at 08:00 GMT | Miami, US

2026 Annual General Meeting (tentative)Investors

March 10, 2026 at 10:30 CET | Basel, Switzerland

BNP Paribas Exane Healthcare ConferenceInvestors

March 24, 2026 at 08:00 GMT | London, UK

Goldman Sachs Biopharma Innovation SummitInvestors

March 25, 2026 at 08:00 GMT | London, UK

Investor relations team contacts

Do you need to get in touch with us? Reach out to our investor relations team with your enquiries.